The ADWP is dedicated to promoting clinical activities, teaching and translational research on autologous/allogeneic HSCT together with novel approaches of cellular therapy as specific treatment of severe Autoimmune Diseases (AD), in a specific challenge to re-induce self-tolerance by resetting the immune system.
The ADs section of the EBMT Registry is the largest database of its kind worldwide. ADs is recently facing a unique developmental phase across EBMT centres. Autologous HSCT has become an integral and standard-of-care part of treatment algorithms in multiple sclerosis (MS) and systemic sclerosis (SSc). Recently, novel cellular therapies (ie CART cells, mesenchymal cells) have been successfully adopted in ADs.
A multidisciplinary approach is key in this field, and the ADWP has the strategic task of interacting with other Autoimmune Diseases (AD) specialists and their respective scientific societies.
ADWP Publications List
Guidelines, Consensus Statements, and Position Papers
Publication guidelines for all studies of the EBMT, Go-CART Coalition and Joint Studies with the WBMT
Proposing the study idea and submitting and selecting the study protocol for EBMT Working Party studies.